BioScreening - organic compounds for screening

30.12.2004 December 2004 Bioscreening News Archive
ChemDiv, Inc. has entered into a collaborative agreement with the Center for Biophysical Sciences and Engineering (CBSE) at the University of Alabama at Birmingham. The partnership will be focused on pharmaceutical discovery for the treatment of osteoporosis and bone loss. Under the terms of the agreement, CBSE will be granted access to the focused libraries designed by Chemical Diversity. In addition, ChemDiv will provide medicinal chemistry services and furnish access to its computational chemistry technologies to accelerate the discovery and lead optimization efforts at CBSE. ChemD-PR 12/30/04

Labcyte will demonstrate its new Echo 380 auditor at the LabAutomation meeting in San Jose, California, January 30 through February 2. The Labcyte® Echo™ 380 auditor determines the fill volume of multi-well plates or sample tubes. Users can interrogate lidded or sealed containers. The technology also allows auditing of containers through most bar codes. With this automated method, there is no risk of contamination or damage to valuable compound libraries. LabCyte-PR 12/27/04
 
Sertanty, Inc., a leading provider of drug discovery cheminformatics products and services, and Specs, a leading supplier of screening compounds and research chemicals, signed a collaboration and service agreement to design and produce small molecule libraries targeting several kinase families. Under the agreement, Sertanty will apply its Kinase KnowledgeBase and predictive eScreen(TM) technology to design targeted libraries that Specs will offer to its worldwide customer base of pharmaceutical and biotechnology companies. Sert-PR 12/21/04

Inpharmatica Ltd, announced a discovery collaboration with Novartis Institutes for BioMedical Research, the pharmaceuticals research organisation of Novartis AG. Under the terms of this agreement, in return for an undisclosed sum, Novartis Discovery Technologies will use Inpharmatica's Chematica™ technology to identify molecular targets, for Novartis' bioactive compound project. Chematica™ is the unique chemogenomics component of PharmaCarta™, Inpharmatica's gene to candidate platform, and seamlessly bridges the gap between biology and chemistry. Chematica™ is capable of target selection through druggability assessment and rapid identification of hits and leads against those targets. Inpharm-PR 12/13/04

Cresset BioMolecular Discovery has launched the FieldScreen™, their proprietary lead-finding and series-switching technology designed to accelerate the selection of leads for targets based on molecular fields rather than traditional molecular structure. FieldScreen™ is a tool that allows users to search through in-house and commercially available compound libraries to select arrays of compounds with diverse structures but the same biological function. What makes this technology unique is that it achieves hit selection by an analysis of the molecular field around the compound and not the molecular structure itself.  Cres-PR 12/09/04

Amnis Corporation has announced the commercial launch of its flagship product, the ImageStream® 100 cell analysis system. The ImageStream system combines the image quality of a microscope and the statistical power of a flow cytometer. The ImageStream system makes possible for the routine high throughput imaging of non- adherent cells and allows high-speed, multi-spectral, fluorescent microscopic analysis of cells-in-flow. These capabilities are enabling researchers to conduct advanced analyses of cell populations for drug discovery and development, and for diagnostic uses. Amn-PR 12/6/04
More bioscreening news...